查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1392004

凝血酶抑制劑市場：依類型、應用、地區

Thrombin Inhibitor Market, By Type, By Application (Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, and Others ), By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計2023年全球凝血酶抑制劑市場規模為307.5億美元，2023-2030年預測期間複合年成長率為6.2%，2030年將達468.5億美元。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 307.5億美元
實績資料 2018-2021 預測期 2023-2030
預測期複合年成長率 6.20% 2030年市場規模預測 468.5億美元
圖 1. 2023 年依地區分類的凝血酶抑制劑的全球市場佔有率(%)
凝血酶抑制劑市場-IMG1

凝血酶抑制劑是一種抗凝血劑（或起抗凝血劑作用的一類藥物），可與凝血酶結合並抑制其活性，從而防止血栓形成。用於預防動、靜脈血栓症，預防及治療深層靜脈栓塞症，預防心房顫動時的血栓性栓塞症。

凝血酶抑制劑治療的疾病包括急性冠狀動脈症候群、心臟血小板減少性疾病、肝素誘發的血小板減少症（HIT）、靜脈血栓栓塞症（VTE）、心房顫動（Afib）、深層靜脈栓塞症（DVT）、肺動脈栓塞等。

目前醫療保健專業人員使用的直接凝血酶抑制劑包括阿加曲班（靜脈注射）、比伐盧定（靜脈注射）和達比加群（錠劑）。

市場動態：

深層靜脈栓塞症(DVT)、肺動脈栓塞(PE) 和心房顫動(AF) 的盛行率/發生率不斷增加，對安全有效治療的需求（由於全世界人們的認知不斷提高）研發(R&D) 的增加，以及新型抗凝血劑的引入是預計推動全球凝血酶抑制劑市場成長的主要因素。

例如，2018年6月，Mylan NV宣佈在美國推出注射用比伐盧定，學名藥。本產品為 250 mg 單劑量給藥，是一種直接凝血酶抑制劑，可用作患者的抗凝血劑。在美國食品藥物管理局(FDA)核准該產品的簡略新藥認證申請 (ANDA) 後，邁蘭 (Mylan) 正在向醫院和機構提供比伐盧定。

本研究的主要特點

  • 該報告對全球凝血酶抑制劑市場進行了詳細分析，並列出了預測期（2023-2030）的市場規模和複合年成長率。
  • 該報告還揭示了各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 該報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 該報告根據以下參數（例如公司亮點、產品系列、主要亮點、績效和策略）介紹了全球凝血酶抑制劑市場的主要企業。
  • 該報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出資訊的決策。
  • 全球凝血酶抑制劑市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球凝血酶抑制劑市場的各種策略矩陣，將有助於相關人員做出決策。

目錄：

第1章 研究目的與假設

  • 研究目標
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章凝血酶抑制劑市場－冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章凝血酶抑制劑市場，依類型，2018-2030

  • 介紹
  • 直接凝血酶抑制劑
  • 間接凝血酶抑制劑

第6章凝血酶抑制劑市場，依應用分類，2018-2030

  • 介紹
  • 深層靜脈栓塞症（DVT）
  • 肺動脈栓塞（PE）
  • 心房顫動 (AF)
  • 其他（中風預防、急性冠狀動脈症候群等）

第7章凝血酶抑制劑市場，依地區，2018-2030

  • 介紹
  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 東南亞國協
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第8章競爭形勢

  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Portola Pharmaceuticals, Inc.
  • CSL Behring
  • Johnson & Johnson
  • Sanofi SA
  • Bayer AG
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company
  • Aspen Pharmacare Holdings Limited

第9章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5835

The global thrombin inhibitor market is estimated to be valued at US$ 30.75 billion in 2023 and is expected to reach US$ 46.85 billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 30.75 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.20% 2030 Value Projection: US$ 46.85 Bn
Figure 1. Global Thrombin Inhibitor Market Share (%), by Region, 2023
Thrombin Inhibitor Market - IMG1

Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin, and therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as prevent and treat deep vein thrombosis and as prophylaxis in atrial fibrillation to avoid thromboembolism.

The conditions treated with thrombin inhibitors are; Acute Coronary Syndrome, Blood clots in heart, Heparin-induced thrombocytopenia (HIT), Venous thromboembolism (VTE), Atrial Fibrillation (Afib), Deep vein thrombosis (DVT), Pulmonary Embolism.

Direct thrombin inhibitor drugs that healthcare providers currently use include; Argatroban (IV injection), Bivalirudin (IV injection), Dabigatran (pill form).

Market Dynamics:

The increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), a rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel the growth of the global thrombin inhibitor market.

For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

Key features of the study:

  • This report provides an in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030)
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, product portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market

Detailed Segmentation:

  • By Type:
    • Direct Thrombin Inhibitors
    • Indirect Thrombin Inhibitors
  • By Application:
    • Deep Vein Thrombosis (DVT)
    • Pulmonary Embolism (PE)
    • Atrial Fibrillation (AF)
    • Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Eisai Co., Ltd.
    • Merck & Co., Inc.
    • Novartis International AG
    • GlaxoSmithKline plc
    • AbbVie Inc.
    • Portola Pharmaceuticals, Inc.
    • CSL Behring
    • Johnson & Johnson
    • Sanofi S.A.
    • Bayer AG
    • Pfizer Inc.
    • Bristol Myers Squibb
    • Boehringer Ingelheim GmbH
    • Daiichi Sankyo Company
    • Aspen Pharmacare Holdings Limited

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Thrombin Inhibitor, By Type
    • Market Thrombin Inhibitor, By Application
    • Market Thrombin Inhibitor, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Thrombin Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Thrombin Inhibitor Market, By Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Direct Thrombin Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Indirect Thrombin Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Thrombin Inhibitor Market, By Application, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Deep Vein Thrombosis (DVT)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Pulmonary Embolism (PE)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Atrial Fibrillation (AF)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Thrombin Inhibitor Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

8. Competitive Landscape

  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Portola Pharmaceuticals, Inc.
  • CSL Behring
  • Johnson & Johnson
  • Sanofi S.A.
  • Bayer AG
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company
  • Aspen Pharmacare Holdings Limited
  • Analyst Views

9. Section

  • Research Methodology
  • About us